AgomAb Therapeutics NV (AGMB) stock
AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$5.82−0.10 (-1.69%)
Close on Nov 18, 2026Market cap $145.50KP/E –Yield –
AgomAb Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
No revenue figures for AgomAb Therapeutics
AgomAb Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?